Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 17;28(11):1697–1709. doi: 10.1177/13524585221093789

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Cohort selection. (a) Flow chart of study design and patient disposition. (b) Proportions of patients meeting 2017 McDonald criteria at baseline and in follow-up. Baseline criteria were evaluated on the baseline MRI (acquired within 45 days from clinical onset), in participants with non-ADEM presentation whose MRI scans were performed with administration of gadolinium-based contrast agent. Fulfillment of the McDonald criteria over time was assessed in all participants including at their most recent follow-up; median (IQR) of 8.14 (6.19–9.80) years in MOG-IgG positive participants and of 6.11 (4.06–9.25) years in MOG-IgG negative participants.

ADS: acquired demyelinating syndrome; ADEM: acute disseminated encephalomyelitis; AQP-4: aquaporin-4; CSF: cerebrospinal fluid; GAD: gadolinium-based contrast agent enhancement; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; NMO: neuromyelitis optica; OCB: oligoclonal band; ON: optic neuritis; TM: transverse myelitis.